Quick Takeaways
- UPB - Upstream Bio, Inc. has 14 insiders with reported activity on this page.
- Net insider value flow over the last year: -$46,571.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 14 Insiders of Upstream Bio, Inc.
- Symbol
- UPB on Nasdaq
- Location
- Waltham, MA
What Changed
- Buy value: ; sell value: $46,570.
- Net share flow: -5,013.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$46,571.
Buys
$0
Shares: 0
Insiders: 0
Sells
$46,571
Shares: 5,013
Insiders: 5
Net
-$46,571
Shares: -5,013
Insiders: -5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 5,013 | $0 | $46,571 | -$46,571 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Upstream Bio, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Everett Rand Sutherland | Chief Executive Officer, Director | $677,306 | -$19,444 | -2.8% | Filing P/S | 16 Mar 2026 |
| Aaron Deykin | Chief Medical Officer | $303,662 | -$8,305 | -2.7% | Filing P/S | 16 Mar 2026 |
| Michael Gray | CFO and COO | $275,429 | -$7,915 | -2.8% | Filing P/S | 16 Mar 2026 |
| Adam Houghton | Chief Business Officer | $225,756 | -$6,494 | -2.8% | Filing P/S | 16 Mar 2026 |
| Allison Ambrose | General Counsel | $153,517 | -$4,413 | -2.8% | Filing P/S | 16 Mar 2026 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Liam Ratcliffe | Director | Mixed | 10 Jun 2025 | |||
| Marcella K. Ruddy | Director | Mixed | 10 Jun 2025 | |||
| Daniella Beckman | Director | Mixed | 10 Jun 2025 | |||
| AI Upstream LLC | 10%+ Owner | Mixed | 15 Oct 2024 | |||
| Erez Chimovits | Director | Mixed | 10 Jun 2025 | |||
| Harold Edward Fleming | Director | Mixed | 10 Jun 2025 | |||
| Ronald C. Renaud Jr. | Director | Mixed | 10 Jun 2025 |
Top shareholders of Upstream Bio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
|
Company |
15%
from 13D/G
|
7,518,202
|
$204,119,193 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
3/4/5
|
Company · Director, 10%+ Owner |
10%
|
5,693,589
|
$154,580,941 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.2%
|
3,344,504
|
$90,803,284 | — | 31 Dec 2025 | |
| Decheng Capital LLC |
13F
|
Company |
5.8%
|
3,143,078
|
$85,334,568 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
2,882,647
|
$78,263,866 | — | 31 Dec 2025 | |
| Enavate Sciences GP, LLC |
13F
|
Company |
4.5%
|
2,459,703
|
$66,780,936 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.4%
|
2,388,439
|
$64,846,119 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
3.3%
|
1,806,243
|
$49,039,498 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2.8%
|
1,527,958
|
$41,422,941 | — | 31 Dec 2025 | |
| HBM Healthcare Investments (Cayman) Ltd. |
13D/G
|
— |
4.1%
|
2,195,111
|
$41,290,257 | -$9,780,217 | 30 Sep 2025 | |
| TCG Crossover GP I, LLC |
13D/G
|
— |
3.9%
|
2,117,103
|
$39,822,919 | -$12,878,523 | 30 Sep 2025 | |
| Altshuler Shaham Ltd |
13F
|
Company |
2.5%
|
1,341,540
|
$36,422,811 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
2.4%
|
1,329,544
|
$36,097,120 | — | 31 Dec 2025 | |
| Omega Fund Management, LLC |
13F
|
Company |
2.4%
|
1,326,293
|
$36,008,855 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.4%
|
1,319,226
|
$35,816,986 | — | 31 Dec 2025 | |
| VR Adviser, LLC |
13F
|
Company |
2.2%
|
1,169,298
|
$31,746,441 | — | 31 Dec 2025 | |
| Decheng Capital Global Life Sciences Fund IV, L.P. |
13D/G
|
Xiangmin Cui |
6.1%
|
3,285,293
|
$29,501,931 | $0 | 31 Dec 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.6%
|
894,733
|
$24,292,001 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
851,908
|
$23,134,004 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.5%
|
834,559
|
$22,658,277 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.4%
|
773,148
|
$20,990,968 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
760,252
|
$20,640,842 | — | 31 Dec 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.4%
|
750,000
|
$20,362,500 | — | 31 Dec 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.4%
|
743,886
|
$20,196,505 | — | 31 Dec 2025 | |
| Samsara BioCapital, LLC |
13F
|
Company |
1.4%
|
736,047
|
$19,983,676 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.3%
|
720,000
|
$19,548,000 | — | 31 Dec 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.1%
|
588,450
|
$15,976,418 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.97%
|
524,499
|
$14,240,148 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.95%
|
517,264
|
$14,043,718 | — | 31 Dec 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.91%
|
494,971
|
$13,438,463 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.63%
|
343,791
|
$9,333,926 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.61%
|
333,481
|
$9,054,009 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
0.55%
|
300,000
|
$8,145,000 | — | 31 Dec 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.55%
|
298,329
|
$8,099,632 | — | 31 Dec 2025 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
0.53%
|
288,847
|
$7,842,196 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.52%
|
284,931
|
$7,735,877 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.44%
|
236,799
|
$6,429,094 | — | 31 Dec 2025 | |
| Squadron Capital Management LLC |
13F
|
Company |
0.42%
|
230,650
|
$6,262,148 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.3%
|
163,186
|
$4,430,500 | — | 31 Dec 2025 | |
| Boxer Capital Management, LLC |
13F
|
Company |
0.28%
|
150,000
|
$4,072,500 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.24%
|
127,815
|
$3,470,177 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.22%
|
122,068
|
$3,314,146 | — | 31 Dec 2025 | |
| SummitTX Capital, L.P. |
13F
|
Company |
0.22%
|
116,724
|
$3,169,057 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.21%
|
115,807
|
$3,144,159 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.2%
|
110,280
|
$2,994,102 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.16%
|
87,756
|
$2,382,576 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.16%
|
86,384
|
$2,345,325 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
84,853
|
$2,303,760 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.14%
|
78,568
|
$2,133,121 | — | 31 Dec 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.14%
|
75,402
|
$2,047,164 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Upstream Bio, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Gray | UPB | Common Stock | Sale | -2.79% | $7,915 | $9.29 | -852 | 29,648 | 16 Mar 2026 | Direct |
| Aaron Deykin | UPB | Common Stock | Sale | -2.66% | $8,305 | $9.29 | -894 | 32,687 | 16 Mar 2026 | Direct |
| Everett Rand Sutherland | UPB | Common Stock | Sale | -2.79% | $19,444 | $9.29 | -2,093 | 72,907 | 16 Mar 2026 | Direct |
| Allison Ambrose | UPB | Common Stock | Sale | -2.79% | $4,413 | $9.29 | -475 | 16,525 | 16 Mar 2026 | Direct |
| Adam Houghton | UPB | Common Stock | Sale | -2.8% | $6,494 | $9.29 | -699 | 24,301 | 16 Mar 2026 | Direct |
| Michael Gray | UPB | Common Stock | Award | 30,500 | 30,500 | 02 Jan 2026 | Direct | |||
| Michael Gray | UPB | Stock Option (Right to Buy) | Award | 91,500 | 91,500 | 02 Jan 2026 | Direct | |||
| Aaron Deykin | UPB | Common Stock | Award | 2024% | 32,000 | 33,581 | 02 Jan 2026 | Direct | ||
| Aaron Deykin | UPB | Stock Option (Right to Buy) | Award | 96,000 | 96,000 | 02 Jan 2026 | Direct | |||
| Allison Ambrose | UPB | Common Stock | Award | 17,000 | 17,000 | 02 Jan 2026 | Direct | |||
| Allison Ambrose | UPB | Stock Option (Right to Buy) | Award | 51,000 | 51,000 | 02 Jan 2026 | Direct | |||
| Adam Houghton | UPB | Common Stock | Award | 25,000 | 25,000 | 02 Jan 2026 | Direct | |||
| Adam Houghton | UPB | Stock Option (Right to Buy) | Award | 75,000 | 75,000 | 02 Jan 2026 | Direct | |||
| Everett Rand Sutherland | UPB | Common Stock | Award | 75,000 | 75,000 | 02 Jan 2026 | Direct | |||
| Everett Rand Sutherland | UPB | Stock Option (Right to Buy) | Award | 225,000 | 225,000 | 02 Jan 2026 | Direct | |||
| Ronald C. Renaud Jr. | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Erez Chimovits | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Marcella K. Ruddy | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Daniella Beckman | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Harold Edward Fleming | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct | |||
| Liam Ratcliffe | UPB | Stock Option (Right to Buy) | Award | 17,096 | 17,096 | 10 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.